Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Tazverik on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Tazverik (tazemetostat) is an EZH2 inhibitor approved by the FDA for two indications: treatment of adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, and treatment of adult patients with relapsed or refractory follicular lymphoma whose tumor is EZH2-mutated (as detected by an FDA-approved test) or who have no satisfactory alternative treatment options.
Tazverik inhibits EZH2, an enzyme involved in regulating gene expression. In epithelioid sarcoma, loss of the INI1/SMARCB1 protein leads to dependence on EZH2 activity for tumor growth, while in certain follicular lymphomas, mutations in the EZH2 gene itself drive abnormal cell proliferation. Blocking EZH2 helps slow tumor growth in both settings.
Tazverik is used in two distinct populations: patients with epithelioid sarcoma not eligible for surgical removal, and patients with relapsed or refractory follicular lymphoma, particularly those with a confirmed EZH2 mutation.
The recommended dose of Tazverik is 800 mg taken orally twice daily, continued until disease progression or unacceptable toxicity.
Tazverik does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia, have been reported. Patients should be monitored for signs of secondary cancers during and after treatment.
Tazverik may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Tazverik is metabolized through CYP3A. Concomitant use with strong or moderate CYP3A inhibitors or inducers should be avoided or approached with caution, as directed by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Tazverik is manufactured and marketed by Epizyme, Inc., an Ipsen company. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating oncologist confirming diagnosis and, where applicable, EZH2 mutation testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for epithelioid sarcoma and EZH2-mutated follicular lymphoma, Tazverik is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Tazverik directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Tazverik should not be stored above 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Tazverik through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Tazverik access.
Delhi's major hospitals assist patients with prescription support and documentation for Tazverik.
Bangalore's specialist network offers access coordination for eligible sarcoma and lymphoma patients seeking Tazverik.
Chennai-based oncology specialists coordinate Tazverik access alongside comprehensive cancer care.
Hyderabad's care institutions support patients pursuing Tazverik therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Tazverik.
Pune-based specialists assist with prescription support and Tazverik treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Tazverik.
Kochi's specialist units assist patients with the documentation needed for Tazverik access.
Chandigarh's care centers support Tazverik treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Tazverik access process.
Lucknow-based centers assist patients pursuing Tazverik therapy.
Bhubaneswar's institutions support access to Tazverik for eligible patients.
Guwahati's specialists help coordinate Tazverik access for patients across the Northeast.
Patients in other cities across India can also access Tazverik through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
